<DOC>
	<DOCNO>NCT00707408</DOCNO>
	<brief_summary>This multicenter open-label phase II trial high dose imatinib mesylate patient AML first second relapse , refractory disease . Daily dose imatinib 600 mg/day plan one month progression disease . Dose increase 800 mg/ day imatinib permit 2 additional month event response failure . Response assess 1 , 2 3 month treatment bone marrow aspirate .</brief_summary>
	<brief_title>High-Dose Imatinib Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>Daily dose imatinib 600 mg/day plan one month progression disease . Dose increase 800 mg/ day imatinib permit 2 additional month event response failure . Novartis provide supply imatinib patient include study .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>age &gt; 18 year , AML first second relapse , refractory AML performance status 02 Eastern Cooperative Oncology Group scale , adequate hepatic renal function ( AST ALT &lt; = 5 time upper limit normal creatinine &lt; 2 time upper limit normal ) 20 % blast bone marrow , 70 % bone marrow blast population ckit positive assess immunophenotyping BcrAbl negative chromosomal analysis ( assessed fluorescence situ hybridization ; FISH ) , chromosome 512 translocation Previous treatment Imatinib Secondary AML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>